#ViaBenefits #GLP1 #Medicare Medicare GLP-1 Bridge Program Expands Obesity Treatment Options CMSs Medicare GLP-1 Bridge Program expands access to obesity treatments for Part D enrollees, raising key considerations for employers and retiree strategies
Not because they distrust doctors, but because these platforms are accessible, fast, and low-cost, which is what they've come to expect in every part of their lives
Enhanced self-monitoring and accountability are fundamental, as frequent tracking of weight and behaviors is a consistent predictor of weight loss success [43]
Short-term use is common due to potential risks like rebound hyperpigmentation and ochronosis
Palmitoylation may be a key factor influencing protein sorting into extracellular vesicles ( Zdhhc21 dep/dep mice exhibited reduced levels of palmitoylation, leading to a decrease in the complement component of EVs, which in turn attenuated neutrophil activation and their lung infiltration, ultimately significantly improving survival (162)
The manufacturer stopped making this drug in 2006, and it is no longer FDA-approved for this purpose